Robert Torray
Torray Fund
Torray Fund Amgen Inc stake
total: 71
Torray Fund AMGN trades
- Total transactions:
- 5
- New positions:
- 1
- Added:
- 2
- Reduced:
- 2
- Held since:
- 2024 Q4
- Held for:
- 7 quarters
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Torray Fund holds 45,000 Amgen Inc (AMGN) shares with a market value of roughly $15.16M accounting for 4.27% of the overall portfolio. To date, the estimated cost basis is nearly $288.66 for "buy" trades and estimated average "sell" price is $363.49. Torray Fund first purchased AMGN in 2024 Q4, initially acquiring 40,660 shares. Since the initial investment in Amgen Inc (AMGN), Torray Fund has made 4 more transactions.
When did Torray Fund buy Amgen Inc (AMGN)?
Torray Fund first invested in Amgen Inc (AMGN) in 2024 Q4 at the reported quarter-end price of $282.87 per share.
What's the cost basis of Torray Fund's AMGN stake?
The estimated cost basis for Amgen Inc (AMGN) stake is around $288.66 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $288.66
- Weighted AVG sell price:
- $363.49
Torray Fund's historical trades in Amgen Inc
5 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
4.27%
|
45,000
|
$336.79
|
$15,155,550
|
+12.50% (+5,000)
|
+0.47%
|
|
2026 Q1
|
4.55%
|
40,000
|
$388.16
|
$15,526,400
|
-11.11% (-5,000)
|
-0.54%
|
|
2025 Q4
|
4.35%
|
45,000
|
$345.46
|
$15,545,700
|
-13.19% (-6,840)
|
-0.65%
|
|
2025 Q2
|
4.51%
|
51,840
|
$288.18
|
$14,939,251
|
+27.50% (+11,180)
|
+0.97%
|
|
2024 Q4
|
3.19%
|
40,660
|
$282.87
|
$11,501,494
|
new
|
+3.19%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.